Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016114542> ?p ?o ?g. }
- W2016114542 endingPage "4035" @default.
- W2016114542 startingPage "4024" @default.
- W2016114542 abstract "Primary cutaneous CD30(+) lymphoproliferative disorders (CD30(+) LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30(+) LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30(+) LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30(+) LPDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30(+) LPDs." @default.
- W2016114542 created "2016-06-24" @default.
- W2016114542 creator A5002644565 @default.
- W2016114542 creator A5002809901 @default.
- W2016114542 creator A5008492560 @default.
- W2016114542 creator A5010943353 @default.
- W2016114542 creator A5017654631 @default.
- W2016114542 creator A5030460763 @default.
- W2016114542 creator A5032585744 @default.
- W2016114542 creator A5040812031 @default.
- W2016114542 creator A5041361796 @default.
- W2016114542 creator A5042319853 @default.
- W2016114542 creator A5048199617 @default.
- W2016114542 creator A5051459543 @default.
- W2016114542 creator A5058782928 @default.
- W2016114542 creator A5064136350 @default.
- W2016114542 creator A5064428344 @default.
- W2016114542 creator A5068469347 @default.
- W2016114542 creator A5068807193 @default.
- W2016114542 creator A5069079748 @default.
- W2016114542 creator A5069645530 @default.
- W2016114542 creator A5075947127 @default.
- W2016114542 creator A5077630026 @default.
- W2016114542 creator A5079170974 @default.
- W2016114542 creator A5087333640 @default.
- W2016114542 creator A5089297467 @default.
- W2016114542 creator A5090297468 @default.
- W2016114542 creator A5090696492 @default.
- W2016114542 date "2011-10-13" @default.
- W2016114542 modified "2023-10-18" @default.
- W2016114542 title "EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*" @default.
- W2016114542 cites W1495282143 @default.
- W2016114542 cites W1557609739 @default.
- W2016114542 cites W1586739835 @default.
- W2016114542 cites W1786189196 @default.
- W2016114542 cites W1850002090 @default.
- W2016114542 cites W1865467061 @default.
- W2016114542 cites W1963675546 @default.
- W2016114542 cites W1966563821 @default.
- W2016114542 cites W1967402899 @default.
- W2016114542 cites W1968554137 @default.
- W2016114542 cites W1969430134 @default.
- W2016114542 cites W1969591058 @default.
- W2016114542 cites W1970743086 @default.
- W2016114542 cites W1970792035 @default.
- W2016114542 cites W1972712927 @default.
- W2016114542 cites W1976493398 @default.
- W2016114542 cites W1976541396 @default.
- W2016114542 cites W1978467228 @default.
- W2016114542 cites W1978483019 @default.
- W2016114542 cites W1978977730 @default.
- W2016114542 cites W1980225576 @default.
- W2016114542 cites W1986043360 @default.
- W2016114542 cites W1986274117 @default.
- W2016114542 cites W1991274353 @default.
- W2016114542 cites W1991532098 @default.
- W2016114542 cites W1992769898 @default.
- W2016114542 cites W1995266245 @default.
- W2016114542 cites W1997381581 @default.
- W2016114542 cites W1998277746 @default.
- W2016114542 cites W1999101270 @default.
- W2016114542 cites W1999191556 @default.
- W2016114542 cites W2006122340 @default.
- W2016114542 cites W2006947385 @default.
- W2016114542 cites W2010148757 @default.
- W2016114542 cites W2011118089 @default.
- W2016114542 cites W2016798575 @default.
- W2016114542 cites W2020715189 @default.
- W2016114542 cites W2022445097 @default.
- W2016114542 cites W2022764036 @default.
- W2016114542 cites W2025996259 @default.
- W2016114542 cites W2026341963 @default.
- W2016114542 cites W2027519886 @default.
- W2016114542 cites W2031344534 @default.
- W2016114542 cites W2031894735 @default.
- W2016114542 cites W2032147924 @default.
- W2016114542 cites W2033819538 @default.
- W2016114542 cites W2034440718 @default.
- W2016114542 cites W2034796130 @default.
- W2016114542 cites W2035418956 @default.
- W2016114542 cites W2042634818 @default.
- W2016114542 cites W2043229195 @default.
- W2016114542 cites W2043374570 @default.
- W2016114542 cites W2043761406 @default.
- W2016114542 cites W2045733649 @default.
- W2016114542 cites W2046215665 @default.
- W2016114542 cites W2049348132 @default.
- W2016114542 cites W2050213014 @default.
- W2016114542 cites W2050857755 @default.
- W2016114542 cites W2051128334 @default.
- W2016114542 cites W2053769912 @default.
- W2016114542 cites W2056484279 @default.
- W2016114542 cites W2057427051 @default.
- W2016114542 cites W2058023882 @default.
- W2016114542 cites W2058524910 @default.
- W2016114542 cites W2059510756 @default.
- W2016114542 cites W2062894247 @default.
- W2016114542 cites W2067431286 @default.